Sign up
Pharma Capital

Genprex updates on positive results for its lung cancer drug Oncoprex

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner updates Proactive Investors on the latest developments with the Texas-based company's non-small cell lung cancer drug, including positive study results done in humanized mice.

Varner says the study of its lead drug Oncoprex at The University of Texas MD Anderson Cancer Center was completed in April after examining the effects of the tumor suppressor gene TUSC2 found in Oncoprex in combination with immunotherapy treatment.


View full GNPX profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.